WeissLaw LLP Reminds PTI, MVC, and EIDX Shareholders About Its Ongoing Investigations

NEW YORK, Nov. 23, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and

would like to discuss our investigations or have any questions concerning

this notice or your rights or interests, please contact:

Joshua Rubin, Esq.

WeissLaw LLP

1500 Broadway, 16^th Floor

New York, NY  10036

(212) 682-3025

(888) 593-4771

stockinfo@weisslawllp.com

Proteostasis Therapeutics, Inc. PTI

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc. PTI in connection with the company's proposed merger with Yumanity Therapeutics, Inc. ("Yumanity").  Under the terms of the agreement, PTI will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of PTI common stock, with existing PTI shareholders owning only 32.5% of the new entity.  If you own PTI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/proteostasis-therapeutics-inc/

MVC Capital, Inc. MVC

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of MVC Capital, Inc. MVC in connection with the proposed acquisition of the company by Barings BDC, Inc. ("BBDC").  Under the terms of the acquisition agreement, MVC shareholders will receive 0.94024 shares of BBDC common stock and $0.39 in cash for each share of MVC common stock that they own, representing implied per-share merger consideration of approximately $8.60 based upon BBDC's November 20, 2020 closing price of $8.71.  If you own MVC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/mvc-capital-inc/   

Eidos Therapeutics, Inc. EIDX

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Eidos Therapeutics, Inc. EIDX in connection with the proposed interested-party acquisition of the company by BridgeBio Pharma, Inc. ("BridgeBio").  Under the terms of the acquisition agreement, EIDX shareholders can elect to receive either 1.85 shares of BridgeBio or $73.26 for each share of EIDX common stock that they own, subject to proration such that the aggregate cash portion will not exceed $175 million.  If you own EIDX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/eidx/

View original content to download multimedia:http://www.prnewswire.com/news-releases/weisslaw-llp-reminds-pti-mvc-and-eidx-shareholders-about-its-ongoing-investigations-301179325.html

SOURCE WeissLaw LLP